Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA.
Mapp Biopharmaceutical, Inc. 6160 Lusk Blvd, San Diego, CA 92121, USA.
Toxins (Basel). 2020 Mar 29;12(4):215. doi: 10.3390/toxins12040215.
PB10 IgG, a monoclonal antibody (MAb) directed against an immunodominant epitope on the enzymatic subunit (RTA) of ricin toxin (RT), has been shown to passively protect mice and non-human primates from an aerosolized lethal-dose RT challenge. However, it was recently demonstrated that the therapeutic efficacy of PB10 IgG1 is significantly improved when co-administered with a second MAb, SylH3, targeting RT's binding subunit (RTB). Here we report that the PB10/SylH3 cocktail is also superior to PB10 alone when used as a pre-exposure prophylactic (PrEP) in a mouse model of intranasal RT challenge. The benefit of the PB10/SylH3 cocktail prompted us to engineer a humanized IgG1 version of SylH3 (huSylH3). The huPB10/huSylH3 cocktail proved highly efficacious in the mouse model, thereby opening the door to future testing in non-human primates.
PB10 IgG 是一种针对蓖麻毒素(RT)酶亚基(RTA)免疫显性表位的单克隆抗体(MAb),已被证明可使小鼠和非人类灵长类动物免受气溶胶化致死剂量 RT 挑战的被动保护。然而,最近的研究表明,当 PB10 IgG1 与第二种针对 RT 结合亚基(RTB)的 MAb SylH3 联合使用时,其治疗效果显著提高。在这里,我们报告说,在 RT 鼻内挑战的小鼠模型中,作为暴露前预防性(PrEP)药物,PB10/SylH3 鸡尾酒的效果也优于单独使用 PB10。PB10/SylH3 鸡尾酒的益处促使我们设计了一种针对 SylH3 的人源化 IgG1 版本(huSylH3)。huPB10/huSylH3 鸡尾酒在小鼠模型中证明非常有效,从而为未来在非人类灵长类动物中的测试开辟了道路。